Paradigm shift cardiac technology advances
Clinical & Experimental Cardiology

Clinical & Experimental Cardiology
Open Access

ISSN: 2155-9880

Paradigm shift cardiac technology advances

8th Cardiovascular Nursing & Nurse Practitioners Meeting

August 08-09, 2016 Las Vegas, USA

Dave Fornell

Diagnostic and Interventional Cardiology, USA

Posters & Accepted Abstracts: J Clin Exp Cardiology

Abstract :

There are several technological advances that may change the current standards of care for cardiology in the coming years. These new technologies are coming at the same time the U.S. healthcare system is undergoing major reforms and they may contribute to efforts to reduce costs, cut lengths of stay, enable easier delivery of care and reduce complication rates. This technology also might simplify management of patients with chronic cardiac conditions, like atrial fibrillation and heart failure. The newest technologies are also part of a larger trend in healthcare toward minimally invasive and noninvasive diagnostic and therapy options. These will eventually reduce the number of open-heart surgeries, diagnostic catheterizations and enable complex procedures such as heart valve replacement to be conducted as out-patient procedures. This technology update report will discuss advances across the cardiovascular subspecialties of interventional cardiology, electrophysiology, structural heart repair, heart valve repair and replacement, heart failure management and cardiac imaging. FDA cleared technologies entering practice include transcatheter aortic replacement (TAVR); left atrial appendage (LAA) occlusion; implantable cardiac monitors; leadless implantable cardioverter defibrillators (ICDs); and fractional flow reserve computed tomography (FFR-CT) for noninvasive assessment of coronary blockages. There are also several new technologies that may have major impacts on care in the future that are now entering FDA investigation device exemption trials or under current FDA review. These technologies include fully bioresorbable stents; transcatheter delivered leadless pacemakers; transcatheter mitral valves and annuloplasty systems; and implantable early warning monitors for new onset of myocardial infarction in previously treated heart attack patients.

Biography :

Email: [email protected]